Barclays lowered the firm’s price target on Avantor (AVTR) to $23 from $26 and keeps an Overweight rating on the shares post the Q4 report. The ...

Life sciences company Avantor (NYSE:AVTR) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling ...

Full Year 2024 Results Key Financial Results Revenue: US$6.78b (down 2.6% from FY 2023).

Q4 2024 Management View Michael Stubblefield, CEO, highlighted Avantor's return to growth in Q4 2024 with low single-digit organic growth and strong bioprocessing performance, achieving high ...

What Happened? Shares of life sciences company Avantor (NYSE:AVTR) fell 9.4% in the afternoon session after the company ...

Companies in the Materials sector have received a lot of coverage today as analysts weigh in on EMS-CHEMIE HOLDING AG (EMSHF – Research ...

Avantor AVTR released its Q4 earnings on Friday, February 7, 2025 at 06:05 AM. Here's what's important from the earnings ...

Analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for Avantor in a research report issued to ...

Avantor's Q4 net sales missed estimates, but adjusted EPS beat expectations. The company projects 2025 organic revenue growth ...

Avantor recorded slightly lower sales in its fourth quarter due to unfavorable foreign exchange rates, though its earnings were boosted by a divestiture. The biopharma supplier posted a profit of $500 ...

Michael Stubblefield, CEO, highlighted Avantor's return to growth in Q4 2024 with low single-digit organic growth and strong bioprocessing performance, achieving high single-digit organic growth ...